{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Galbraith MD"],"funding":["National Institute of Allergy and Infectious Diseases","National Center for Advancing Translational Sciences","Anna and John J Sie Foundation","Global Down Syndrome Foundation","Boettcher Foundation","Lyda Hill Foundation","National Heart, Lung, and Blood Institute","National Cancer Institute","National Institute of General Medical Sciences"],"pagination":["e65508"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7963480"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10"],"pubmed_abstract":["COVID19 is a heterogeneous medical condition involving diverse underlying pathophysiological processes including hyperinflammation, endothelial damage, thrombotic microangiopathy, and end-organ damage. Limited knowledge about the molecular mechanisms driving these processes and lack of staging biomarkers hamper the ability to stratify patients for targeted therapeutics. We report here the results of a cross-sectional multi-omics analysis of hospitalized COVID19 patients revealing that seroconversion status associates with distinct underlying pathophysiological states. Low antibody titers associate with hyperactive T cells and NK cells, high levels of IFN alpha, gamma and lambda ligands, markers of systemic complement activation, and depletion of lymphocytes, neutrophils, and platelets. Upo"],"journal":["eLife"],"pubmed_title":["Seroconversion stages COVID19 into distinct pathophysiological states."],"pmcid":["PMC7963480"],"funding_grant_id":["RM1GM131968","3UL1TR002535-03S2","UL1TR002535","R35GM124939","P30CA046934","3R01AI150305-01S1","R01AI145988","R01AI150305","R21HL150032","R01HL149714","R01HL148151"],"pubmed_authors":["D'Alessandro A","Araya P","Galbraith MD","Granrath RE","Smith KP","Kinning KT","Espinosa JM","Hansen KC","Benett TD","Ghosh T","Russell S","Dzieciatkowska M","Shaw JR","Monte AA","Sullivan KD","Baxter R","Hsieh EW","Jordan KR"],"additional_accession":[]},"is_claimable":false,"name":"Seroconversion stages COVID19 into distinct pathophysiological states.","description":"COVID19 is a heterogeneous medical condition involving diverse underlying pathophysiological processes including hyperinflammation, endothelial damage, thrombotic microangiopathy, and end-organ damage. Limited knowledge about the molecular mechanisms driving these processes and lack of staging biomarkers hamper the ability to stratify patients for targeted therapeutics. We report here the results of a cross-sectional multi-omics analysis of hospitalized COVID19 patients revealing that seroconversion status associates with distinct underlying pathophysiological states. Low antibody titers associate with hyperactive T cells and NK cells, high levels of IFN alpha, gamma and lambda ligands, markers of systemic complement activation, and depletion of lymphocytes, neutrophils, and platelets. Upo","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2025-04-18T16:40:44.434Z","creation":"2025-04-07T04:03:40.165Z"},"accession":"S-EPMC7963480","cross_references":{"pubmed":["33724185"],"doi":["10.7554/eLife.65508"]}}